Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and underlying etiologies from 1990 to 2015 at the Global, Regional, and National Level: results from the global burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683–91.

Article  PubMed  PubMed Central  Google Scholar 

Teng YX, Xie S, Guo PP, Deng ZJ, Zhang ZY, Gao W, et al. Hepatocellular Carcinoma in non-alcoholic fatty liver disease: current progresses and challenges. J Clin Transl Hepatol. 2022;10(5):955–64.

Article  PubMed  PubMed Central  Google Scholar 

Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022;34(7):969–e772.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20–30.

Article  PubMed  Google Scholar 

Su JY, Deng ZJ, Teng YX, Koh YX, Zhang WG, Zheng MH et al. Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis. BJS Open. 2023;7(1):zrac167.

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835.

Article  PubMed  Google Scholar 

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.

Article  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven proposed nomenclature for metabolic Associated fatty liver disease. Gastroenterology. 2020;158(7):1999–e20141.

Article  CAS  PubMed  Google Scholar 

Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500–14.

Article  CAS  PubMed  Google Scholar 

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–64.

Article  PubMed  Google Scholar 

Liu L, Xie S, Teng YX, Deng ZJ, Chen K, Liu HT, et al. Outcomes of Liver Resection for Metabolic Dysfunction-Associated fatty liver Disease or Chronic Hepatitis B-Related HCC. Front Oncol. 2021;11:783339.

Article  CAS  PubMed  Google Scholar 

Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology. 2018;67(5):2001–12.

Article  PubMed  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of Liver diseases. Hepatology. 2018;67(1):328–57.

Article  PubMed  Google Scholar 

Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404–10.

Article  CAS  PubMed  Google Scholar 

[Chinese guidelines for lipid management. (2023)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2023;51(3):221– 55.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

Rolland B, Chazeron I, Carpentier F, Moustafa F, Viallon A, Jacob X, et al. Comparison between the WHO and NIAAA criteria for binge drinking on drinking features and alcohol-related aftermaths: results from a cross-sectional study among eight emergency wards in France. Drug Alcohol Depend. 2017;175:92–8.

Article  PubMed  Google Scholar 

Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, Behari J, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55(6):1809–19.

Article  PubMed  Google Scholar 

Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521–30.

Article  PubMed  PubMed Central  Google Scholar 

Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578–88.

Article  PubMed  Google Scholar 

Kaya E, Yilmaz Y. Metabolic-associated fatty liver Disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329–38.

Article  PubMed  Google Scholar 

Joseph CA, Yi-Te L, Vatche GA, Yazhen Z, Sungyong Y, Hsian-Rong T, et al. Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Res. 2022;8:10.

Google Scholar 

Eliza WB, Leva G, Jaclyn V, Lindsey S, Ann Scheck M, Allan T. Barriers to surveillance for hepatocellular cancer among patients with chronic liver disease -providers’ perspectives. Hepatoma Res. 2023;9:45.

Article  Google Scholar 

Yuan BH, Li RH, Huo RR, Li MJ, Papatheodoridis G, Zhong JH. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J Gastroenterol Hepatol. 2022;37(5):782–94.

Article  CAS  PubMed  Google Scholar 

Pan LX, Wang YY, Li ZH, Luo JX, Wu KJ, Liu ZX, et al. Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial. Trials. 2024;25(1):25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang QX, Xue J, Shi MJ, Xie YB, Xiao HM, Li S, et al. Association between Metabolic Dysfunction-Associated fatty liver Disease and the risk of cirrhosis in patients with chronic Hepatitis B-A Retrospective Cohort Study. Diabetes Metab Syndr Obes. 2022;15:2311–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flemming JA, Djerboua M, Groome PA, Booth CM, Terrault NA. NAFLD and Alcohol-Associated Liver Disease Will be responsible for almost all New diagnoses of cirrhosis in Canada by 2040. Hepatology. 2021;74(6):3330–44.

Article  PubMed  Google Scholar 

Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175–83.

Article  CAS  PubMed  Google Scholar 

Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, et al. Hepatitis C Virus infection is Associated with increased Cardiovascular Mortality: a Meta-analysis of Observational studies. Gastroenterology. 2016;150(1):145–55..e4; quiz e15-6.

Article  PubMed  Google Scholar 

Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, et al. Prevalence and treatment of diabetes in China, 2013–2018. JAMA. 2021;326(24):2498–506.

Article  PubMed  PubMed Central  Google Scholar 

Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with Diabetes, chronic kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China. J Clin Endocrinol Metab. 2022;107(1):88–97.

Article  PubMed  Google Scholar 

Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1 Suppl):S69–78.

Article  PubMed  Google Scholar 

Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV Extrahepatic manifestations. J Clin Transl Hepatol. 2019;7(2):172–82.

PubMed  PubMed Central  Google Scholar 

Du T, Sun X, Yuan G, Zhou X, Lu H, Lin X, et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism. 2016;65(9):1391–8.

Article  CAS  PubMed  Google Scholar 

Xuan Y, Gao P, Shen Y, Wang S, Gu X, Tang D, et al. Association of hypertriglyceridemic waist phenotype with non-alcoholic fatty liver disease: a cross-sectional study in a Chinese population. Horm (Athens). 2022;21(3):437–46.

Article  Google Scholar 

Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.

Article  PubMed  Google Scholar 

Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, et al. Cardiovascular Risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver. 2022;16(2):290–9.

Article  CAS  PubMed  Google Scholar 

Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-Associated fatty liver Disease and Incident Cardiovascular Disease Risk: a Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2021;19(10):2138–e4710.

Article  PubMed  Google Scholar 

Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56(11):1022–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):637–53.

Article